<DOC>
	<DOC>NCT02686918</DOC>
	<brief_summary>The main of this study is to assess the feasibility of a patients follow-up visit receiving trastuzumab subcutaneous by Advanced Practice Nurse.</brief_summary>
	<brief_title>Feasibility Assessment of a Patients Follow-up Visit Receiving Trastuzumab Subcutaneous by Advanced Practice Nurse</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Patient care at the Cancer Institute Lucien Neuwirth Patient aged over 18 years Patient with breast cancer overexpressing HER2 adjuvant Patient having finished their chemotherapy treatment with IV followed the oncologist day hospital Patient under Trastzumab subcutaneously Patient affiliated or entitled to a social security scheme (mandatory requirement for all studies) Refusal to participate, most patient protected under guardianship. Patient in inability to understand the course of the study Patient with documented history of cognitive or psychiatric disorders. Patients pregnant or lactating Patients under guardianship or curatorship</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>